Vaccines and Related Biological Products Advisory Committee; Notice of Meeting, 491-492 [2015-33263]
Download as PDF
Federal Register / Vol. 81, No. 3 / Wednesday, January 6, 2016 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
The purpose of the public meeting is
to report on FDA’s progress
implementing the Action Plan, to
discuss how stakeholders have been
affected by these changes, and to solicit
feedback and recommendations for
further implementation from interested
parties and stakeholders.
Some questions we would like the
public to comment on during the
meeting include:
1. What approaches have been
successful in addressing key barriers to
recruiting diverse clinical trial
populations?
2. What are your key limitations to
conducting meaningful data analysis of
underrepresented groups?
3. What have you learned about best
practices for recruiting a broad
representation of subjects for clinical
trials? Which practices have been
successful and why? Which have not
and why?
4. What communication strategies
have you successfully used that were
also sensitive to the needs of
underrepresented populations?
5. What are potential methods FDA
should consider using to effectively
communicate meaningful information
on demographic analyses to a diverse
public?
6. What are some of the actual or
potential unintended consequences of
data transparency you have encountered
related to reporting demographic
subgroup analysis?
Stakeholders are invited to provide
brief comments on these topics during
the public comment portion of the
meeting, but are not limited to
discussing only the previous topics.
Since the day-long meeting may not
provide enough time to fully address all
of these issues, we encourage interested
groups to submit longer explanations
and comments to the docket.
II. Registration and Request for Oral
Presentations
FDA will try to accommodate all
participant requests to speak; however,
the duration of comments may be
limited by time constraints. Those
wishing to make oral presentations will
be asked to send a brief summary of
their comments and registration
information (including name, title, firm
name, address, telephone, email
address, and fax number), and should
register by February 1, 2016, by
emailing FDASIA907@fda.hhs.gov.
All other participants are asked to
register online at: https://www.fda.gov/
ForHealthProfessionals/
LearningActivities/ucm470074.htm by
February 13, 2016, whether they plan to
attend in person or listen to the meeting
VerDate Sep<11>2014
17:32 Jan 05, 2016
Jkt 238001
on a live Webcast. Registration is free
and will be on a first-come, first-served
basis. Onsite registration on the day of
the meeting will be based on space
availability. Information on how to
access the Webcast will be posted
approximately 5 days before the meeting
at: https://www.fda.gov/
ForHealthProfessionals/
LearningActivities/ucm470074.htm.
If you need special accommodations
due to a disability, please contact
FDASIA907@fda.hhs.gov at least 7 days
in advance. Persons attending the public
meeting are advised that FDA is not
responsible for providing access to
electrical outlets.
Dated: December 30, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–33261 Filed 1–5–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–0001]
Vaccines and Related Biological
Products Advisory Committee; Notice
of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Vaccines and
Related Biological Products Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on March 4, 2016, from 8:30 a.m.
to 3 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993–
0002. For those unable to attend in
person, the meeting will also be Web
cast and will be available at the
following link https://
collaboration.fda.gov/vrbpac030416/.
Answers to commonly asked questions
including information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
491
AboutAdvisoryCommittees/
ucm408555.htm.
Contact Person: Sujata Vijh or Denise
Royster, Center for Biologics Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 6128, Silver Spring,
MD 20993–0002, 240–402–7107 or 240–
402–8158, email: Sujata.vijh@
fda.hhs.gov or denise.royster@
fda.hhs.gov or FDA Advisory Committee
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area). A notice in the Federal Register
about last minute modifications that
impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the Agency’s Web
site at https://www.fda.gov/
AdvisoryCommittees/default.htm and
scroll down to the appropriate advisory
committee meeting link, or call the
advisory committee information line to
learn about possible modifications
before coming to the meeting.
Agenda: On March 4, 2016, the
committee will meet in open session to
discuss and make recommendations on
the selection of strains to be included in
the influenza virus vaccines for the
2016–2017 influenza season.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before February 19, 2016.
Oral presentations from the public will
be scheduled between approximately
12:40 p.m. and 1:40 p.m. Those
individuals interested in making formal
oral presentations should notify the
contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before February 10, 2016. Time
allotted for each presentation may be
E:\FR\FM\06JAN1.SGM
06JAN1
492
Federal Register / Vol. 81, No. 3 / Wednesday, January 6, 2016 / Notices
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. The contact
person will notify interested persons
regarding their request to speak by
February 11, 2016.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Sujata Vijh at
least 7 days in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: December 31, 2015.
Leslie Kux,
Associate Commissioner for Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on DSK4VPTVN1PROD with NOTICES
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; X01’s BRAC Review.
Jkt 238001
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: December 31, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–33256 Filed 1–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute on Drug Abuse
Notice of Closed Meeting
BILLING CODE 4164–01–P
17:32 Jan 05, 2016
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
National Institutes of Health
[FR Doc. 2015–33263 Filed 1–5–16; 8:45 am]
VerDate Sep<11>2014
Date: January 14, 2016.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Joel A. Saydoff, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
NINDS/NIH/DHHS/Neuroscience Center,
6001 Executive Boulevard, Suite 3205, MSC
9529, Bethesda, MD 20892–9529, 301–435–
9223, joel.saydoff@nih.gov.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Development of Primer and Reference Tool to
Assess Neonatal Abstinence Syndrome
(1210).
Date: January 15, 2016.
Time: 11:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–402–6626,
gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 31, 2015.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–33252 Filed 1–5–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
Confirmatory Efficacy Clinical Trials of NonPharmacological Interventions for Mental
Disorders.
Date: January 21, 2016.
Time: 12:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Marcy Ellen Burstein,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6143, MSC 9606,
Bethesda, MD 20892–9606, 301–443–9699,
bursteinme@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
Interventions.
Date: January 28, 2016.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\06JAN1.SGM
06JAN1
Agencies
[Federal Register Volume 81, Number 3 (Wednesday, January 6, 2016)]
[Notices]
[Pages 491-492]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-33263]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2015-N-0001]
Vaccines and Related Biological Products Advisory Committee;
Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Vaccines and Related Biological Products
Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
Date and Time: The meeting will be held on March 4, 2016, from 8:30
a.m. to 3 p.m.
Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building
31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD
20993-0002. For those unable to attend in person, the meeting will also
be Web cast and will be available at the following link https://collaboration.fda.gov/vrbpac030416/. Answers to commonly asked
questions including information regarding special accommodations due to
a disability, visitor parking, and transportation may be accessed at:
https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.
Contact Person: Sujata Vijh or Denise Royster, Center for Biologics
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 71, Rm. 6128, Silver Spring, MD 20993-0002, 240-
402-7107 or 240-402-8158, email: Sujata.vijh@fda.hhs.gov or
denise.royster@fda.hhs.gov or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in
the Federal Register about last minute modifications that impact a
previously announced advisory committee meeting cannot always be
published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.
Agenda: On March 4, 2016, the committee will meet in open session
to discuss and make recommendations on the selection of strains to be
included in the influenza virus vaccines for the 2016-2017 influenza
season.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
February 19, 2016. Oral presentations from the public will be scheduled
between approximately 12:40 p.m. and 1:40 p.m. Those individuals
interested in making formal oral presentations should notify the
contact person and submit a brief statement of the general nature of
the evidence or arguments they wish to present, the names and addresses
of proposed participants, and an indication of the approximate time
requested to make their presentation on or before February 10, 2016.
Time allotted for each presentation may be
[[Page 492]]
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person will
notify interested persons regarding their request to speak by February
11, 2016.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
disabilities. If you require accommodations due to a disability, please
contact Sujata Vijh at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: December 31, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-33263 Filed 1-5-16; 8:45 am]
BILLING CODE 4164-01-P